Previous 10 |
Embecta press release (NASDAQ:EMBC): Q2 GAAP EPS of $1.38. Revenue of $274.5M (-3.4% Y/Y). For further details see: Embecta GAAP EPS of $1.38, revenue of $274.5M
PARSIPPANY, N.J., May 13, 2022 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world following its April 1, 2022, spin off from Becton, Dickinson and Company ("BD"), today reported financial results for ...
PARSIPPANY, N.J., May 09, 2022 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (Nasdaq: EMBC) today announced that management will participate in the following upcoming investor conferences: The 2022 RBC Capital Markets Global Healthcare Conference at the Intercontinental NY Barcl...
FRANKLIN LAKES, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (NASDAQ: EMBC) today announced that it will report its financial results for the second quarter of fiscal year 2022 before the market opens on Friday, May 13, 2022. Management will host a conference call ...
News, Short Squeeze, Breakout and More Instantly...
Genpact Supports embecta's Spin-Off into an Independent Diabetes Care Company PR Newswire Genpact's deep domain knowledge and data expertise enables embecta's vision to make a meaningful impact in the healthcare sector NEW YORK , July 29, 2024 /PRNewswire...
PARSIPPANY, N.J., July 18, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal third quarter 2024 financial results, provide an operational upd...
PARSIPPANY, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, presented two abstracts at the American Diabetes Association’s 84 th Scientific Sessions that point to ...